 The objective of this study is to investigate the safety and efficacy of aripiprazole initial dose 2 mgday, maintenance dose 6-24 mgday, maximum dose 30 mgday orally administered over a period of 52 weeks in subjects who complete a short-term treatment study of pediatric patients aged 13-17 years with schizophrenia 031-09-003 study. 